Discovery of selective Toxoplasma gondii dihydrofolate reductase inhibitors for the treatment of toxoplasmosis

Authors

Allen T Hopper, Vyera Pharmaceuticals
Adam Brockman, Vyera Pharmaceuticals
Andy Wise, Evotec (UK) LTD
Julie Gould, Evotec (UK) LTD
Jennifer Barks, Washington University School of Medicine in St. Louis
Joshua B Radke, Washington University School of Medicine in St. Louis
L. David Sibley, Washington University School of Medicine in St. Louis
Yongmao Zou, WuXi AppTec (Tianjin) Co., Ltd
Stephen Thomas, Vyera Pharmaceuticals

Journal

Journal of medicinal chemistry

Publication Date

2-14-2019

Volume

62

Issue

3

First Page

1562

Last Page

1576

Document Type

Open Access Publication

DOI

10.1021/acs.jmedchem.8b01754

Rights and Permissions

Hopper AT, Brockman A, Wise A, Gould J, Barks J, Radke JB, Sibley LD, Zou Y, Thomas S. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019 Feb 14;62(3):1562-1576. doi: 10.1021/acs.jmedchem.8b01754. Copyright © 2019 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

Recommended Citation

Hopper, Allen T; Brockman, Adam; Wise, Andy; Gould, Julie; Barks, Jennifer; Radke, Joshua B; Sibley, L. David; Zou, Yongmao; and Thomas, Stephen, "Discovery of selective Toxoplasma gondii dihydrofolate reductase inhibitors for the treatment of toxoplasmosis." Journal of medicinal chemistry. 62, 3. 1562 - 1576. (2019).
https://digitalcommons.wustl.edu/oa_3/2